Broadcom is a central player in the AI infrastructure cycle, specifically through its networking and application-specific integrated circuit (ASIC) business. Analysts anticipate Broadcom's semiconductor revenue could triple by 2027, with 2026 revenue growth projected at 64%. It serves as a diversified alternative to pure-play chipmakers while maintaining massive exposure to the data center boom.
AMD has solidified its position as the primary challenger to Nvidia in the AI and data center arenas. While its stock can be volatile, long-term investors are increasingly bullish on its lineup of CPUs and AI accelerators. Analysts recommend it for its potential to capture a larger share of the $3 trillion data center market over the next five years. top ten shares to buy today
Meta has successfully integrated AI features into its core advertising business, resulting in 24% revenue growth in recent quarters. Analysts recommend it as an attractive growth stock due to its surging advertising revenue and disciplined cost-cutting measures. By April 2026, its valuation remains attractive to experts who project continued double-digit growth through 2027. Broadcom is a central player in the AI
Amazon continues to be a staple for long-term portfolios due to its dominance in cloud computing (AWS) and e-commerce. In 2026, analysts highlight its strategic focus on infrastructure positioning and cost efficiency as key drivers for high returns. Despite short-term market pressures, it remains a favorite for "buy and hold" investors looking for 20-year stability. AMD has solidified its position as the primary
As the primary manufacturer for tech giants like Nvidia and Apple, TSM is a foundational play for the AI infrastructure boom. After crushing fourth-quarter results with 26% revenue growth, management signaled an aggressive $52–$56 billion capital expenditure plan for 2026 to meet "huge and lasting" chip demand. Analysts forecast significant upside for the year as AI spending continues to accelerate.
Google's parent company remains a pillar of the "Magnificent 7" stocks, though it has seen some double-digit price declines early in 2026. However, analysts view this as a potential entry point for long-term growth, citing its leadership in search-driven AI and its significant weight in major market indices. Stock market outlook April 2026 - Fidelity Investments
The healthcare sector's standout performer is Eli Lilly, primarily due to the ongoing boom in GLP-1 weight-loss drugs. In early 2026, the company reported triple-digit revenue growth for its blockbuster treatments, Mounjaro and Zepbound. Analysts project 26% revenue growth for the full year, supported by an aging population and a "near-guaranteed" growth trajectory for essential medical services.